Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Advances APA-01 SPV Deal; Royalty Stream Contingent on Funding

By The Northwire Desk — AI Analysis May 13, 2026 · 08:30 MDMA · 0.14 Pharmala Biotech Holdings Inc.
Executive Summary
  • Definitive Agreement: PharmAla Biotech has executed a binding agreement with Aluvaris Inc. and Diteba Inc. to form Restora Neurosciences, an SPV for APA-01 development.
  • Equity Split: Founding shares of the SPV are split 50/50 between PharmAla and Aluvaris.
  • Licensing Terms: PharmAla retains IP ownership but grants Restora exclusive worldwide rights to APA-01 (MDXX molecule) for psychological trauma, stroke rehab, and TBI indications.
  • Financial Conditions: The license becomes irrevocable only if the SPV raises US$2,500,000 from third-party investors within three months (extendable by 3).
  • Revenue Recognition: Upon meeting funding threshold, PharmAla receives a one-time fee of $500,000 and a perpetual 3% royalty on net sales.
  • Anti-Dilution: PharmAla maintains a 25% equity floor in Restora through the first priced financing post-initial round.
  • Governance: Four-person board (2 from each party); PharmAla has unilateral veto over IP matters.
  • Timeline: IND filing target is within 36 months of satisfying funding threshold.
Material Impact
  • Execution vs. Surprise: The definitive agreement follows the April 27, 2026 Letter of Intent (LOI) which set a June 8 deadline for closing. Closing on May 13 is consistent with expectations and execution of previously disclosed strategy rather than unexpected market-moving news.
  • Conditional Value: Unlike previous unconditional supply agreements, this deal hinges entirely on the SPV raising $2.5M within three months. Failure to raise capital could result in license revocation or renegotiation, introducing significant execution risk.
  • Cash Flow Impact: Potential immediate cash inflow of $500,000 is modest relative to company size but improves liquidity if funded. The 3% royalty provides long-term upside without diluting PharmAla's balance sheet immediately.
  • Strategic Alignment: Aligns with the April 20 Executive Order response strategy by diversifying beyond MDMA (ALA-002) into novel MDXX molecules, though APA-01 is earlier stage than ALA-002.
  • Market Reaction: The stock price has been consolidating around $0.14-$0.15 following the April 20 spike to $0.18. This news supports the consolidation but lacks the catalyst strength to break resistance levels without confirmed funding.
MDMA · Price
Company Overview
  • Core Business: Supply chain provider for clinical-grade MDMA (LaNeo™) and development of novel MDXX class molecules.
  • Flagship Product: LaNeo™ MDMA is currently generating revenue through the Cortexa JV in Australia and supplying US clinical trials (VA, DHA).
  • Pipeline:
    • ALA-002: Next-generation MDMA formulation with reduced cardiovascular signature; GMP manufacturing initiated; Phase 2a/2b planned for 2026.
    • APA-01: Novel MDXX molecule for trauma/TBI; currently in SPV structure (Restora Neurosciences).
  • Operations: Manufacturing in Australia and UK (CDMO); distribution sites in US, Australia, Europe.
Read the original news release →

More from Pharmala Biotech Holdings Inc.

May 20, 2026 · 08:15

PharmAla’s ALA-002 draws a nine-figure pact with Nasdaq-listed Jupiter, signalling Big Pharma-style validation for next-gen MDMA in a transformed U.S. regulatory landscape.

Other May 20, 2026 · 07:38

PharmAla’s $100M-Plus ALA-002 Licensing Pact with Nasdaq’s Jupiter Validates Next-Gen MDMA, Fueling a Pivotal Re-Rating

M&A / Property Apr 27, 2026 · 08:00

PharmAla Biotech Monetizes APA-01 IP via SPV Amidst Psychedelic Regulatory Tailwinds

Other Apr 21, 2026 · 16:05

PharmAla Biotech Gains on Regulatory Tailwinds as Earnings Confirm Growth Amidst Management Shake-Up

Earnings Apr 20, 2026 · 08:15

CSE: MDMA

Production / Operations Mar 23, 2026 · 09:00

Cortexa Advances Commercialisation of MDMA Supply in Australia

Production / Operations